200 related articles for article (PubMed ID: 18476981)
1. The therapeutic efficacy of rosiglitazone is enhanced in sulphonylurea-treated patients with type 2 diabetes.
Itakura H; Abbasi F; Lamendola C; Basina M; Reaven G
Diabetes Obes Metab; 2008 Aug; 10(8):685-7. PubMed ID: 18476981
[No Abstract] [Full Text] [Related]
2. Thiazolidinedione derivatives in type 2 diabetes mellitus.
Tack CJ; Smits P
Neth J Med; 2006 Jun; 64(6):166-74. PubMed ID: 16788214
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
[No Abstract] [Full Text] [Related]
4. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
[No Abstract] [Full Text] [Related]
5. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes.
Charbonnel B
Int J Clin Pract Suppl; 2007 Jun; (153):1-2. PubMed ID: 17594387
[No Abstract] [Full Text] [Related]
6. Which should we ADOPT: sulphonylureas or glitazones?
Koshiyama H; Inagaki N; Seino Y
Diabet Med; 2007 Jul; 24(7):804. PubMed ID: 17596243
[No Abstract] [Full Text] [Related]
7. Pioglitazone/glimepiride (Duetact) for diabetes.
Med Lett Drugs Ther; 2007 Jan; 49(1253):9-11. PubMed ID: 17261966
[No Abstract] [Full Text] [Related]
8. Pioglitazone + glimepiride: a combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):145. PubMed ID: 17724836
[No Abstract] [Full Text] [Related]
9. New therapeutic options: management strategies to optimize glycemic control.
Sisam DA
J Am Osteopath Assoc; 2011 Apr; 111(4):300; author reply 300. PubMed ID: 21562302
[No Abstract] [Full Text] [Related]
10. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
11. [Pharmacologic treatment of diabetes].
De Montigny P; Clerc C; Descarpentries C
Perspect Infirm; 2006; 4(2):30-4. PubMed ID: 17184094
[No Abstract] [Full Text] [Related]
12. Treating type 2 diabetes: targeting the many causative factors.
Sutherland JE; Hoehns JD
J Fam Pract; 2004 May; 53(5):376-88. PubMed ID: 15125823
[No Abstract] [Full Text] [Related]
13. Drugs for type 2 diabetes.
Treat Guidel Med Lett; 2008 Jul; 6(71):47-54. PubMed ID: 18583949
[No Abstract] [Full Text] [Related]
14. Which oral drug is right for your type 2 diabetes? New thinking on oral drug combinations that can provide better glycemic control.
Health News; 2005 Feb; 11(2):10-1. PubMed ID: 15732153
[No Abstract] [Full Text] [Related]
15. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
Inzucchi SE
Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
[No Abstract] [Full Text] [Related]
16. [Warning signals insulin resistance. Insulin resistance causes not only diabetes].
MMW Fortschr Med; 2004 Jul; 146(29-30):49. PubMed ID: 15540564
[No Abstract] [Full Text] [Related]
17. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study.
Aravind SR; Al Tayeb K; Ismail SB; Shehadeh N; Kaddaha G; Liu R; Balshaw R; Lesnikova N; Heisel O; Girman CJ; Musser BJ; Davies MJ; Katzeff HL; Engel SS; Radican L;
Curr Med Res Opin; 2011 Jun; 27(6):1237-42. PubMed ID: 21506631
[TBL] [Abstract][Full Text] [Related]
18. Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes.
Hu YY; Ye SD; Zhao LL; Zheng M; Wu FZ; Chen Y
Clin Endocrinol (Oxf); 2010 Dec; 73(6):739-43. PubMed ID: 20874769
[TBL] [Abstract][Full Text] [Related]
19. A case of new mutation in maturity-onset diabetes of the young type 3 (MODY 3) responsive to a low dose of sulphonylurea.
Jesić MD; Sajić S; Jesić MM; Maringa M; Micić D; Necić S
Diabetes Res Clin Pract; 2008 Jul; 81(1):e1-3. PubMed ID: 18433912
[TBL] [Abstract][Full Text] [Related]
20. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
